PDF(Pubmed)
Abstract：
Although there has been an effective seasonal influenza vaccine available for more than 60 years, influenza continues to circulate and cause illness. The Eastern Mediterranean Region (EMR) is very diverse in health systems capacities, capabilities, and efficiencies, which affect the performance of services, especially vaccination, including seasonal influenza vaccination.
The aim of this study is to provide a comprehensive overview on country-specific influenza vaccination policies, vaccine delivery, and coverage in EMR.
We have analyzed data from a regional seasonal influenza survey conducted in 2022, Joint Reporting Form (JRF), and verified their validity by the focal points. We also compared our results with those of the regional seasonal influenza survey conducted in 2016.
Fourteen countries (64%) had reported having a national seasonal influenza vaccine policy. About (44%) countries recommended influenza vaccine for all SAGE recommended target groups. Up to 69% of countries reported that COVID-19 had an impact on influenza vaccine supply in the country, with most of them (82%) reporting increases in procurement due to COVID-19.
The situation of seasonal influenza vaccination in EMR is varied, with some countries having well established programs while others having no policy or program; these variances may be due to resources inequity, political, and socioeconomic dissimilarities. Few countries have reported wide vaccination coverage over time with no clear trend of improvement.
We suggest supporting countries to develop a roadmap for influenza vaccine uptake and utilization, assessment of barriers, and burden of influenza, including measuring the economic burden to enhance vaccine acceptance.
The aim of this study is to provide a comprehensive overview on country-specific influenza vaccination policies, vaccine delivery, and coverage in EMR.
We have analyzed data from a regional seasonal influenza survey conducted in 2022, Joint Reporting Form (JRF), and verified their validity by the focal points. We also compared our results with those of the regional seasonal influenza survey conducted in 2016.
Fourteen countries (64%) had reported having a national seasonal influenza vaccine policy. About (44%) countries recommended influenza vaccine for all SAGE recommended target groups. Up to 69% of countries reported that COVID-19 had an impact on influenza vaccine supply in the country, with most of them (82%) reporting increases in procurement due to COVID-19.
The situation of seasonal influenza vaccination in EMR is varied, with some countries having well established programs while others having no policy or program; these variances may be due to resources inequity, political, and socioeconomic dissimilarities. Few countries have reported wide vaccination coverage over time with no clear trend of improvement.
We suggest supporting countries to develop a roadmap for influenza vaccine uptake and utilization, assessment of barriers, and burden of influenza, including measuring the economic burden to enhance vaccine acceptance.
摘要：
尽管已有60多年的有效季节性流感疫苗，流感继续传播并导致疾病。东地中海地区(EMR)的卫生系统能力非常多样化，能力,和效率，影响服务的性能，特别是疫苗接种，包括季节性流感疫苗接种。
■这项研究的目的是全面概述针对特定国家的流感疫苗接种政策，疫苗交付，以及EMR的覆盖范围。
■我们分析了2022年进行的区域性季节性流感调查的数据，联合报告表（JRF），并通过焦点验证了它们的有效性。我们还将我们的结果与2016年进行的区域性季节性流感调查的结果进行了比较。
■14个国家（64％）报告了国家季节性流感疫苗政策。大约（44％）的国家推荐所有SAGE推荐的目标群体使用流感疫苗。高达69%的国家报告说，COVID-19对该国的流感疫苗供应产生了影响，其中大多数（82%）报告说，由于COVID-19，采购增加。
■EMR的季节性流感疫苗接种情况各不相同，一些国家有完善的方案，而另一些国家没有政策或方案；这些差异可能是由于资源不平等，政治,和社会经济差异。很少有国家报告疫苗接种覆盖率随着时间的推移而没有明显的改善趋势。
■我们建议支持各国制定流感疫苗摄取和利用的路线图，评估障碍，和流感的负担，包括衡量经济负担以提高疫苗接受度。
■这项研究的目的是全面概述针对特定国家的流感疫苗接种政策，疫苗交付，以及EMR的覆盖范围。
■我们分析了2022年进行的区域性季节性流感调查的数据，联合报告表（JRF），并通过焦点验证了它们的有效性。我们还将我们的结果与2016年进行的区域性季节性流感调查的结果进行了比较。
■14个国家（64％）报告了国家季节性流感疫苗政策。大约（44％）的国家推荐所有SAGE推荐的目标群体使用流感疫苗。高达69%的国家报告说，COVID-19对该国的流感疫苗供应产生了影响，其中大多数（82%）报告说，由于COVID-19，采购增加。
■EMR的季节性流感疫苗接种情况各不相同，一些国家有完善的方案，而另一些国家没有政策或方案；这些差异可能是由于资源不平等，政治,和社会经济差异。很少有国家报告疫苗接种覆盖率随着时间的推移而没有明显的改善趋势。
■我们建议支持各国制定流感疫苗摄取和利用的路线图，评估障碍，和流感的负担，包括衡量经济负担以提高疫苗接受度。
